Development of a new injectable medication called TAK-243.
Official title: NEXT DTP-22-013, PRODUCTION OF TAK-243 INJECTABLE FOR CLINICAL USE
Funded at Irisys, INC. · NIH-10710314 · Data updated 2026-11-12
This study is looking at a new injectable medicine called TAK-243 to make sure it stays safe and effective for patients, so they can eventually use it in their treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Irisys, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | April 11, 2022 |
| Project end | April 10, 2026 |
| Funding year | 2022 |
| Award (this year) | $639,151 |
| NIH project number | 75N98019D00058-0-759102200003-1 |
| Project ID | NIH-10710314 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals who may benefit from the therapeutic effects of TAK-243.
✕Less likely to help
Patients who do not have conditions that TAK-243 is designed to treat may not receive any benefit from this research.
What this research studies
This research focuses on producing TAK-243, an injectable medication intended for clinical use. The project will investigate the stability and shelf-life of this medication to ensure its effectiveness when administered to patients. By ensuring that TAK-243 can be safely stored and used, the research aims to facilitate its availability for patient treatment. Patients may be involved in trials to assess the medication's safety and efficacy once it is ready for clinical application.
Why it matters
Potential benefit: If successful, this research could provide patients with a new treatment option that is stable and effective.
How similar studies have gone: While the production of injectable medications is a common practice, the specific development of TAK-243 is a novel approach that has not been extensively tested in prior studies.
Where this research is happening
-
Irisys, INC.
San Diego, United States Active
Researchers
- Principal investigator: Giannini, Robert — Irisys, INC.
- Study coordinator: Giannini, Robert
Related research
Other NIH-funded projects on the same topics.
-
Developing and testing a new medication formulation for clinical trials.
This study is working on a new way to deliver a medication called ORC-13661, which could help patients by making the treatment more effective, and it will be tested in a clinical trial to ensure it's safe and works well.
-
Developing and testing a new oral medication in tablet form.
This study is working on making a new tablet medication called NCGC72 and will test it in early trials to see how safe it is and how well it works for patients.
-
Developing and testing a new oral medication formulation.
This study is working on making a new tablet medication called NCGC72, which could help patients, by ensuring it's safe, effective, and stays good for a long time before it’s tested in people.
-
Production of Z-Endoxifen capsules for treatment.
This study is working on creating a new type of capsule called Z-Endoxifen that people can take by mouth to help treat certain health conditions, making sure it's safe and effective for patients.
-
Investigating a new cancer treatment using AZA-TDC capsules.
This study is testing a new cancer treatment called AZA-TDC capsules to see how well it works and how safe it is for patients, and it's looking for people to help find out if this new option is better than what’s already available.
-
Creating capsules of ammonium tetrathiomolibdate for clinical use
This study is working on creating special capsules that contain a new treatment for patients, and it aims to make sure these capsules are safe and effective for future clinical trials.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.